OPIANT PHARMACEUTICALS INC OPNT
July 28, 2018 - 2:53pm EST by
BJG
2018 2019
Price: 14.00 EPS 0 0
Shares Out. (in M): 3 P/E 0 0
Market Cap (in $M): 36 P/FCF 0 0
Net Debt (in $M): -11 EBIT 0 0
TEV ($): 25 TEV/EBIT 0 0

Sign up for free guest access to view investment idea with a 45 days delay.

 

Description

I do not hold a position with the issuer such as employment, directorship, or consultancy.
I and/or others I advise hold a material investment in the issuer's securities.

Catalyst

  • Majority of Narcan royalty fully reflected in financials beginning Q2 2018 following royalty reversion trigger in Q1.
  • OPNT001 - phase 2 last patient Q4 2018 with data readout Q1 2019.
  • OPNT002 - phase 2 initiates in Q4 2018 with first patient enrollment in Q1 2019.
  • OPNT005 - NIH grant decision expected during Q1 2019.
    sort by    
      Back to top